Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veterinary Anticancer Peptide Therapeutics Development

Inquiry Now
Overview One-stop Service Mechanism Applications Platform Service WorkflowRelated Research Why Choose Us? Case Study FAQs

BioVenic offers veterinary anticancer peptide (ACP) therapeutics development services providing a one-stop alternative to conventional cancer treatments, supporting veterinary oncology research, anticancer drug discovery, and preclinical therapeutic development. Our platform covers ACP discovery and assay development and screening, synthesis and purification, activity assays, design and sequence analysis, formulation, manufacturing, and quality control, synthetic/medicinal/process chemistry, in vitro ADME, in vitro and in vivo pharmacology, and pharmacokinetic research, supported by dedicated discovery, screening, synthetic, pharmacology, and assessment platforms. We support researchers across livestock, companion animals, poultry, and aquatic species with ACPs engineered to inhibit tumor proliferation, migration, and angiogenesis via immunomodulation, membrane lysis, anti-angiogenic, and apoptosis-inducing mechanisms, delivering species-specific, modifiable, and cost-effective cancer therapeutics.

Anticancer Peptide Therapeutics Development Overview

BioVenic offers a one-stop solution for the development of anticancer peptide therapeutics, encompassing a comprehensive platform for preclinical research. This integrated approach includes the discovery, screening, synthesis, and pharmacological testing of anticancer peptides, aimed at addressing various cancer mechanisms effectively. By managing the entire development process—from initial research through to quality control and product delivery—BioVenic ensures the creation of effective and innovative therapeutics for veterinary medicine.

Fig.1 The summary of veterinary anticancer peptide therapeutics development. (BioVenic Original)Fig.1 The mechanism of veterinary anticancer peptide therapeutics development. (BioVenic Original)

Anticancer Peptide Therapeutics Development One-stop Service

To support the preclinical research and development of anticancer peptide therapeutics, BioVenic offers a tailored suite of services designed to optimize peptide efficacy and safety. These comprehensive services include:

  • Anticancer peptide discovery.
  • Assay development & screening.
  • Anticancer peptide synthesis and purification.
  • Anticancer peptide activity assay service.
  • Anticancer peptide design and sequence analysis.
  • Anticancer peptide formulation, manufacturing, and quality control.
  • Anti-cancer peptide synthetic, medicinal & process chemistry.
  • In vitro ADME of anticancer peptides.
  • In vitro & in vivo pharmacology of anti-cancer peptide.
  • Pharmacokinetics research.

Anticancer Peptide Therapeutics Mechanism

  • Immunomodulation
    Anticancer peptides can enhance the immune system's ability to recognize and destroy cancer cells. They may activate various immune cells or increase the presentation of cancer cell antigens, facilitating an immune response specifically targeted at tumor cells.
  • Cancer Cell Membrane Lysis
    Anticancer peptides can disrupt the integrity of cancer cell membranes, leading to cell lysis. They interact with the lipid components of the cell membrane, forming pores or causing membrane breakdown, which results in cell death.
  • Anti-angiogenic Effects
    Anticancer peptides can inhibit the growth of new blood vessels that tumors need to grow and spread. By blocking angiogenesis, these peptides starve the tumor of necessary nutrients and oxygen, hindering its growth and metastasis.
  • Cytochrome C Release
    By inducing the release of cytochrome C from mitochondria, anticancer peptides initiate apoptosis in cancer cells. This process leads to programmed cell death, effectively reducing tumor viability and progression.

Anticancer Peptide Therapeutics Applications

Species Applications
Livestock Utilized to manage and treat cancers such as bovine leukemia and squamous cell carcinoma in cattle, and other tumors prevalent in large animals.
Companion animals Commonly used to treat cancers in dogs and cats, such as lymphoma, melanoma, and mammary gland tumors, improving quality of life and survival rates.
Aquatic animals Effective in treating tumors in fish species commonly found in aquaculture, enhancing health and sustainability in commercial fish farming.
Poultry Applied in managing avian cancers, such as Marek's disease and avian leukosis, to reduce mortality and improve flock health.

Our Technical Platform

BioVenic provides a robust array of technical platforms designed to support the development and evaluation of veterinary anticancer peptides, including:

  • Anticancer Peptide Discovery Platform
  • Anticancer Peptide Screening Platform
  • Anticancer Peptide Synthetic Platform
  • In vitro & In vivo Pharmacology Analysis Platform
  • Assessment Platform

BioVenic specializes in offering diverse peptide development services, each tailored to discover novel therapeutic peptides. Please explore the following links for more detailed information on our comprehensive offerings.

Service Workflow

The development of veterinary anticancer peptide therapeutics involves five key steps:

  1. Inquiry: Assess needs and applications to set the foundation for targeted development.
  2. Anticancer Peptide Discovery: Identify potential peptides for cancer treatment preclinical research in animals using our discovery and screening platform.
  3. Development and Validation: Conduct tests to optimize peptides for efficacy and safety in preclinical models.
  4. Manufacturing and Quality Control: Produce peptides under strict standards to ensure purity and consistency.
  5. Report and Product Delivery: Deliver detailed documentation and final products, completing the development cycle.

Fig.2 The service workflow of veterinary anticancer peptide therapeutics development. (BioVenic Original)Fig.2 The veterinary anticancer peptide therapeutics development service workflow. (BioVenic Original)

Related Research

In a single-arm Phase 2 clinical trial, researchers evaluated the safety, immunogenicity, and therapeutic efficacy of an adjuvant, secretome-derived peptide-based vaccine in 28 dogs with aggressive hemangiosarcoma following standard-of-care (SOC) surgical resection and doxorubicin chemotherapy. The immunogenic secretome vaccine was engineered by infecting primary canine hemangiosarcoma cell cultures with Salmonella typhi Ty21a, a process that triggers the upregulation and functional opening of connexin 43 (CX43) hemichannels to release endoplasmic reticulum stress-related peptides into the extracellular milieu. Administered across five serial doses every three weeks post-SOC, the autologous peptide formulation elicited both a tumor-specific humoral response and a vaccine-specific T-cell-mediated immune response without inducing systemic or organ-specific toxicity. Compared to a retrospective control cohort of 32 dogs receiving SOC alone, the addition of the peptide vaccine demonstrated superior biophysical efficacy, significantly extending the median time to progression from 160 to 195 days, improving median overall survival from 175 to 276 days, and elevating the one-year survival rate from 6.3% to 35.7%.

Determine the average titer of the vector genome using qPCR and ddPCR.Fig. 3 S. typhi Ty21a infection induces upregulation and opening of CX43 hemichannels on hemangiosarcoma primary cells, allowing the release of immunogenic peptides.1

Why Choose Us?

  • One-stop Solution: A seamless process from initial assessment to final product delivery, simplifying the development of veterinary anticancer therapeutics.
  • Advanced Technical Platforms: Cutting-edge technologies accelerate peptide discovery and optimization, ensuring rapid and effective development.
  • Species-Specific Properties: Tailored anticancer peptides enhance treatment efficacy and safety for specific animal species, improving clinical outcomes.
  • Complex Biological Data Interpretation: Expert analysis of intricate biological data ensures the peptides' effectiveness and suitability for veterinary use.

Case Study

Researchers took a veterinary anticancer peptide from discovery through screening, solid-phase synthesis, and activity validation, then used a selective cytotoxicity profile to establish its therapeutic promise. Cancer cell viability fell sharply as peptide concentration increased, while normal cells remained largely unaffected—opening a clear selective window rather than indiscriminate toxicity. Supported by mechanism studies and in vitro and in vivo pharmacology, the peptide advanced as an optimized preclinical candidate with an evidence-backed safety margin.

Determine the average titer of the vector genome using qPCR and ddPCR.Fig. 4 Selective Cytotoxicity Profile

Frequently Asked Questions

Q1: What types of veterinary tumor or tissue samples are acceptable for your anticancer peptide discovery and validation services?

A: We accept a wide range of veterinary biological samples, including fresh-frozen tumor tissues, formalin-fixed paraffin-embedded (FFPE) blocks, cell lines, and biological fluids (such as serum, plasma, or pleural effusion) from target species like canine, feline, and equine. Samples should be collected following proper aseptic techniques and immediately stored or fixed according to our standard operating protocols. For specific transport conditions, buffer requirements, or sample minimum volume guidelines, we encourage clients to consult with our technical support team prior to shipment.

Q2: Can your anticancer peptide development services be customized for specific animal species and tumor types?

A: Yes, our services are fully customizable to meet the unique physiological characteristics of individual veterinary species and specific cancer types, such as canine osteosarcoma, feline lymphoma, or equine melanoma. We tailor target selection, peptide sequence optimization, and in vitro efficacy assays based on the specific species-derived cell lines or target receptors. Because cross-reactivity and sequence homology vary significantly between companion animals and livestock, we recommend contacting our technical support team to discuss your project requirements and optimize the custom experimental design.

Q3: What in vitro and in vivo models are available for evaluating veterinary anticancer peptide efficacy?

A: We provide a comprehensive panel of assays, including cell proliferation, apoptosis detection, and cell migration/invasion using veterinary-specific cell lines. For downstream evaluation, we support animal model studies through custom xenograft models or syngeneic models tailored to assess therapeutic response, pharmacokinetics, and preliminary safety. Due to regulatory considerations and species-specific model availability, we advise clients to reach out to our technical support staff to confirm model feasibility, study timelines, and compliance requirements.

Q4: What is the typical turnaround time and deliverable package for a custom peptide development project?

A: Turnaround times vary depending on the scope of the project, ranging from several weeks for peptide synthesis and initial in vitro screening to a few months for comprehensive lead optimization and preclinical evaluation. Deliverables typically include high-purity synthetic peptides with detailed Certificate of Analysis (CoA, including HPLC and Mass Spectrometry data), raw assay results, and a comprehensive final study report detailing experimental procedures and conclusions. For a precise timeline estimate and customized milestone schedule, please contact our technical support team.

Our comprehensive one-stop solution simplifies the entire development process for veterinary anticancer peptide therapeutics. Supported by advanced technical platforms and tailored to meet species-specific requirements, we specialize in the preclinical research phase, ensuring precise interpretation of complex biological data. BioVenic is committed to delivering optimized and effective preclinical results. Contact us today to explore how our expert services can transform your anticancer peptide concepts into preclinical reality, specifically designed for veterinary applications.

Reference

  1. Marconato, Laura, et al. "A phase 2, single-arm, open-label clinical trial on adjuvant peptide-based vaccination in dogs with aggressive hemangiosarcoma undergoing surgery and chemotherapy." Cancers 15.17 (2023): 4209. https://doi.org/10.3390/cancers15174209. Used under CC BY 4.0, without modification.
Inquiry Basket